Lab21 acquires Microgen Bioproducts
Microgen Bioproducts’ expertise in microbiological assay development and commercialisation complements Lab21’s diagnostics portfolio particularly in the infectious disease market. This transaction provides further expansion of Lab21’s distribution channel in key territories including the US, UK, Europe and Asia.
Graham Mullis, CEO of Lab21 said: “Microgen Bioproducts is a well established and profitable business which will significantly contribute to our growth plans in our core products division. This acquisition highlights Lab21’s commitment to continuing its exciting roll-up strategy and we expect to bring other high quality acquisitions into the Group during 2011.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.